159 results about "Pet imaging" patented technology

The invention relates to the technical field of molecular probes, and particularly discloses a molecular probe of a targeted tyrosine kinase receptor as well as a preparation method and application of the molecular probe, the molecular probe comprises radioisotope, targeted polypeptide and a chelating group, the targeted polypeptide specifically targets the tyrosine kinase receptor, the chelating group is connected with the targeted polypeptide to form a targeted precursor, and the chelating group is connected with the targeted polypeptide to form the targeted precursor. The radioactive isotope labeled precursor forms a molecular probe, and the sequence of the targeted polypeptide is shown as any one of SEQ ID No.1-8. The targeting polypeptide has good targeting property on a tyrosine kinase receptor coded by an RET gene, can realize specific high uptake in a cell line of NEPC, has relatively good biological safety, can realize accurate imaging aiming at NEPC, and clearly and durably visualizes NEPC tumors in PET imaging; meanwhile, the molecular probe can effectively delay the growth capacity of NEPC, can provide a new treatment choice for NEPC patients, and has good clinical transformation potential.

The invention discloses an early evaluation method, device and system for Alzheimer's disease. The method comprises the following steps: detecting whether a user completes a preset short-term task or not; when the user completes the preset short-term task, acquiring physiological data of the user; inputting the physiological data into an evaluation model to obtain a risk score, the evaluation model being an Alzheimer's disease early evaluation model; and generating an assessment report according to the risk score. According to the method, when the user completes the preset short-term task, the physiological data of the user are collected and input into the Alzheimer's disease early assessment model to obtain the risk score, so that the assessment report is obtained, the assessment report can be obtained without lumbar puncture, PET imaging detection and high-resolution MRI detection of the user, and the user experience is improved. The compliance is improved; the detection cost is reduced; and the detection timeliness is improved.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The invention provides an FAPI trimer compound, a preparation method of the FAPI trimer compound, a PET developer based on the FAPI trimer compound and a preparation method of the developer. Amphipathic polyethylene glycol chains and trimeric structures in molecules of the FAPI trimer compound can improve in-vivo dynamic characteristics of the compound, and the in-vivo dynamic characteristics of the compound can be improved. The residence time in the tumor is prolonged; the PET imaging agent based on the FAPI trimer compound can improve the uptake and imaging effects of the PET imaging agent in tumors, and has good application prospects in PET imaging, preparation of drugs for diagnosing FAP-q expressed tumors and drugs for marking therapeutic nuclide (177Lu or 90Y) to treat the FAP-q expressed tumors in the future.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

The present application provides a preparation method for a liquid composition comprising Compound I and its use in myocardial perfusion PET imaging. The method comprising the following steps: purifying a crude product comprising the compound I by using high-performance liquid chromatography, wherein a mobile phase used in the high-performance liquid chromatography purification step comprises ethanol and water. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale activity production and meet automation needs. An obtained myocardial perfusion PET imaging agent of this application has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or productivity.

A method for estimating noise equivalent counts includes one or more times during a scan of an object with a positron emission tomography (PET) scanner, wherein a plurality of coincidence events are detected by a detector array of the PET scanner, performing the following actions. The actions include obtaining a total of the plurality of coincidence events, estimating random coincidence events, and estimating scatter coincidence events. The actions include estimating true coincidence events based on the total of the plurality of coincidence events, the estimated random coincidence events, and the estimated scatter coincidence events. The actions include determining a scatter fraction based on the estimated scatter events and true coincidence events. The actions include estimating the noise equivalent counts based at least on the scatter fraction, the total of the plurality of coincidence events, the estimated true coincidence events, the estimated scatter coincidence events, and the estimated random coincidence events.

The present invention provides a method for preparing and using a Trop2-specific integrated diagnostic and therapeutic molecular imaging probe. The Trop2-specific molecular imaging probe, constructed based on the Trop2-specific nanoantibodies WWD98 and WWD328, can be used for immuno-PET imaging. Immuno-PET imaging using the probe can non-invasively display Trop2 expression within tumors, achieving non-invasive visualization of human Trop2 molecular expression. This provides a better method for diagnosing and monitoring Trop2-positive solid tumors and can further enable non-invasive diagnosis of various tumors, such as pancreatic cancer and gastric cancer. The probe of the present invention has the advantages of a simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and ease of clinical translation.

The present invention provides a radiolabeled compound targeting cannabinoid receptor type 2 labeled with the radionuclide 18F. The present invention also provides a process for the preparation of said compound and its use as a positron emission tomography (PET) imaging agent.

The invention discloses a polypeptide PET (Polyethylene Terephthalate) developer targeting FGFR1 (Fibroblast Growth Factor Receptor). The structure of the polypeptide PET developer targeting FGFR1 is shown as a formula (1), r1 is a bifunctional chelating group and is selected from at least one of a formula (2) or a formula (3); Mn < + > is marked radionuclide chelated with R1; the radionuclide Mn < + > is selected from at least one of [Al18F] < 2 + >, < 68 > Ga < 3 + >, < 64 > Cu < 2 + > and < 177 > Lu < 3 + >. The structure of the FGFR1-targeted polypeptide PET imaging agent comprises polypeptide, a bifunctional chelating agent and radionuclide, the preparation method is simple and rapid, the yield is high, the PET imaging agent is good in stability, high in water solubility and high in in-vivo blood removal speed, the PET imaging agent is mainly metabolized by the kidney and can be specifically taken by a high-expression tumor site of the FGFR1, and the PET imaging agent can be widely applied to biological function imaging.

The application belongs to the technical field of biological medicine, and discloses a synthesis method of aryl F-18 labeled sulfuryl chloride and application of the aryl F-18 labeled sulfuryl chloride in amine compound labeling. The method takes thiophenol derivative as a labeling precursor, obtains F-18 labeled thiophenol intermediate through photocatalytic aryl F-18 fluorination reaction, and then obtains aryl F-18 labeled sulfuryl chloride through N-chlorosuccinimide oxidation chlorination. The obtained aryl F-18 labeled sulfuryl chloride (4-[ 18 F] fluorobenzenesulfonyl chloride) can occur sulfurylization reaction with various amine compounds at room temperature, and the radiochemical conversion rate is as high as 98%. The application is successfully applied to novel synthesis of AMPA receptor PET imaging agent[ 18 F]2 (the conversion rate is 96%, which is much higher than 13% reported in the literature). The application has the advantages of mild reaction condition, high conversion rate and wide substrate application range, and provides an efficient method for innovative preparation of F-18 labeled PET probes.

A compound or pharmaceutically acceptable salt thereof has at least one bis-phosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po. The positron emitting radionuclide Po is attached to the at least one bisphosphonate or bisphosphonate ester group. The compound may be useful in a method of diagnosis of amyloidosis, such as cardiac amyloidosis.

The invention discloses a PET imaging device for multi-radiation-field particle therapy, PET equipment and a therapy system. The PET imaging device comprises: an identification unit configured to identify one or more time intervals of each radiation field according to time distribution characteristics of collected single event data, each time interval corresponding to a particle beam delivery state; the coincidence processing unit is configured to perform coincidence processing on the single event data to generate coincidence event data; and the reconstruction unit is configured to perform image reconstruction on the coincidence event data in the identified time interval of each radiation field to obtain a reconstructed image corresponding to each radiation field. Through intelligent identification of time distribution characteristics and a partition reconstruction strategy, the problem of serious aliasing of PET signals in a multi-radiation-field delivery mode is solved, and accurate extraction of independent dose distribution of each radiation field and image reconstruction are realized.

The invention provides a pAKT-targeted small molecule compound, a PET molecular probe precursor, a PET molecular probe and a preparation method and application of the PET molecular probe. The PET molecular probe disclosed by the invention is a radioactive probe which is modified on the basis of a chemical structure of a medicine Caprivastib (AZD5363) and is marked by 68Ga and is targeted to pAKT. According to the probe, structural modification is carried out on Capivasertib, the area, combined with PKA, of Capivasertib is changed, precursor molecules combined with pAKT in a high-specificity mode are obtained, and the precursor molecules are further researched, developed and modified into the radioactive probe targeting pAKT capable of being used for PET imaging. The probe has relatively low abdominal nonspecific uptake, can effectively distinguish tumors with high expression and low expression of pAKT in vivo, and can predict and early evaluate the response condition of the tumors to a PI3K / AKT pathway related inhibitor. Therefore, the probe has a very strong clinical application prospect, on one hand, the probe can be used for analyzing the expression quantity of pAKT in tumor tissues; on the other hand, the probe can also be used for predicting and early evaluating the effect of the PI3K / AKT pathway related inhibitor in anti-tumor treatment.

The application discloses a polypeptide PET molecular probe for targeting breast cancer and a preparation method and application thereof. The polypeptide PET molecular probe for targeting breast cancer is obtained by labeling an AR polypeptide modified by a bifunctional chelating agent with a positron emitting radionuclide, and has the advantages of simple synthesis, small molecular weight, high specificity, no immunogenicity and good biological safety. In addition, the polypeptide PET molecular probe has high radiochemical performance and in-vivo and in-vitro stability, can better realize breast cancer targeted PET imaging compared with current commonly used imaging agents, can be used for preparing an imaging agent for breast cancer diagnosis, and is helpful for clinical diagnosis of breast cancer.

The invention belongs to the technical field of biological medicine, and particularly discloses a compound targeting MAT2A and application thereof. The structure of the compound is shown as a formula I in the specification. The compound designed by the invention can be used as a PET imaging probe to realize early accurate diagnosis and staging of MAT2A high-expression tumors and meet the whole-process clinical requirements of'diagnosis-curative effect evaluation 'of solid tumors.

The invention discloses an early evaluation method, device and system for Alzheimer's disease. The method comprises the following steps: acquiring magnetic resonance imaging data and physiological data of a user; inputting the magnetic resonance imaging data and the physiological data into a cross-modal feature fusion model to obtain fusion features; inputting the fusion features into an expert model to obtain a prediction result; and generating an evaluation report according to the prediction result. According to the method, the magnetic resonance imaging data and the physiological data are processed through the cross-modal feature fusion model, so that the high-level fusion features are obtained, then the expert model is used for processing the fusion features, so that the prediction result is obtained, the evaluation report is obtained, a user can obtain the evaluation report without lumbar puncture and PET imaging detection, and the user experience is improved. The compliance is improved; and the detection cost is reduced.

A method for determining a convolution kernel for an iterative statistical algorithm based on a continuous-to-continuous data model. The method is used for image reconstruction from radiation measurements obtained in emission tomography, specifically in a Time-of-Flight Positron Emission Tomography (TOF PET) scanner. The presented method is a non-list-mode solution that reduces the computational complexity of the reconstruction problem, improves the resolution of reconstructed images, reduces the radiation dose absorbed by patients during TOF PET examinations, and / or shortens the measurement acquisition time without significantly compromising the quality of the diagnostic images. Notably, the quality of the functional images remains at the same level. These improvements are achieved by designing the convolution kernel to account for the statistical properties of the measurement signals registered during the TOF PET scanner's acquisition process.

According to the GLP1R targeted radioactive probe, the preparation method and the application, the GLP1R targeted radioactive probe can be specifically combined with GLP1R, has the good in-vivo biological metabolism property, does not cause blood glucose reduction after being injected and is a potential glucagon-like peptide-1 receptor PET imaging probe. The GLP1R targeted radioactive probe is [68Ga] Ga-NOTA-1D32, [68Ga] Ga-NOTA-1D36, or [68Ga] Ga-NOTA-1D39, and the GLP1R targeted radioactive probe is a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe.

The application discloses a method for constructing fluorine-containing compounds by decarboxylation of alkyl carboxylic acid catalyzed by ketone compounds. The method uses alkyl carboxylic acid with a structure as shown in formula as a reaction raw material, and performs reaction under the joint action of ketone compounds, fluorine-containing reagents and alkali to obtain fluorides shown in formula (1) and formula (2), wherein R 1 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 2 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 3 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl. The reaction method has the advantages of low cost, mild conditions, high reaction efficiency, high yield and high selectivity, and the like. The ketone compounds are used to replace traditional metal catalysts, which can not only provide a fluorine-containing compound library with various structures for candidate drug screening, but also can be applied to positron emission tomography imaging.

Provided herein are radiolabelled anti-MET antibodies and MET x MET bispecific antibodies and their use in immune PET imaging. Including methods of detecting the presence of MET protein in a subject or sample and methods of monitoring the efficacy of treatment of Met-expressing tumors.

The present application relates to the field of biological medicine, and provide a kind of targeting PSMA dimer compound and its derivative and application, the structure general formula of the dimer compound is as shown in formula (I).The dimer compound and its derivative of the present application have very high affinity and targeting to PSMA, after being labeled with suitable radionuclide, can be used as nuclear medicine molecular probe, to realize early diagnosis, staging and treatment of prostate cancer, 68 Ga]diPSMA-1-DOTA showed good tumor uptake in PET imaging of tumor mice.Therefore, this kind of radioactive complex has good clinical application prospect in tumor imaging targeting PSMA (especially PET imaging), and lays an important foundation for the radiotherapy application of [ 177 Lu]diPSMA-1-DOTA and [ 225 Ac]diPSMA-1-DOTA.

The application discloses a PET imaging correction method fusing a large model prior. The method comprises the following steps: acquiring a to-be-corrected PET image and structured text information, and then using a trained conditional flow matching network model architecture fusing a large model prior to obtain a corrected PET image, wherein the conditional flow matching network model architecture fusing the large model prior comprises a large model, a multi-core fusion module, a conditional flow matching model and an affine transformation module, the large model is used to generate a text description of the to-be-corrected PET image in accordance with anatomical logic, the multi-core fusion module is used to weight and fuse the PET image and the text information to obtain enhanced image features with text prior information, the conditional flow matching model is used to obtain a predicted vector field through a conditional flow matching process based on the enhanced image features, and then a corrected PET image is obtained through gradual flow according to the predicted vector field. The application can effectively solve the problems of residual artifacts and structural distortion existing in the traditional PET correction method.

This invention discloses a PET image reconstruction method and system based on manifold prior constraints, belonging to the field of medical image reconstruction and intelligent information processing technology. It acquires historical PET image datasets and PET measurement data from positron emission tomography (PET), constructs a data consistency term based on a Poisson statistical model, and introduces the image manifold prior into the PET image reconstruction optimization model. The optimization model is solved using an alternating iterative approach based on variable splitting, including data consistency updates, manifold projection updates, and dual variable updates. Finally, the reconstructed PET image is output. This invention organically combines the PET imaging physical model with data-driven prior generation, which is beneficial for improving reconstructed image quality, suppressing noise, and preserving structural details in low-dose PET imaging scenarios.

Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.

The invention discloses a preparation method of a radioactive probe based on a DTN-SYL3C conjugate and application of the radioactive probe in dynamic PET imaging of EpCAM positive colorectal cancer, and the preparation method of the radioactive probe comprises the following steps: firstly, constructing a T20-DTN-DBCO nano structure through self-assembly by a one-step annealing method; then, an azide modified SYL3C aptamer and the T20-DTN-DBCO nanostructure are subjected to directional coupling, a T20 modified DTN-SYL3C conjugate is obtained, and the T20 modified DTN-SYL3C conjugate is purified through agarose gel electrophoresis; and finally, carrying out complementary pairing on the < 68 > Ga-NOTA-A20 and the T20-DTN-SYL3C through a base, so as to obtain the < 68 > Ga-DTN-SYL3C probe. The radioactive probe provided by the invention can prolong the in-vivo circulation time of the aptamer and improve the targeted uptake of the tumor site, and meanwhile, the pharmacokinetics improvement effect can be accurately quantified by matching with dynamic PET (Polyethylene Terephthalate).

The present application relates to PET imaging of soluble epoxide hydrolase (sEH) 18 F-FNDP. Disclosed herein are radiofluorinated FNDPs for PET imaging of soluble epoxide hydrolase (sEH) and methods of use thereof, in particular, compounds of Formula (I) of the present application and uses thereof are disclosed.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.